Acıbadem Healthcare 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    SUCCESSFULL MANAGEMENT OF POST- CAR-T CELL COLD AGLUTININ MEDIATED REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA WITH DARATUMUMAB (ePoster Area) -  Jan 30, 2022 - Abstract #EBMT2022EBMT_1219;    
     Cold agglutinin mediated hemolytic anemia post CAR-T cell treatment is a complex entity with lack of evidence based treatment . Anti CD38 monoclonal antibody daratumumab induces rapidly depletion of antibody producing plasma cells and can be an option in steroid, IVIG and Rituximab refractory cold agglutinin mediated autoimmune hemolytic anemia in CAR-T cell patients.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    SUCCESSFULL MANAGEMENT OF POST- CAR-T CELL COLD AGLUTININ MEDIATED REFRACTORY AUTOIMMUNE HEMOLYTIC ANEMIA WITH DARATUMUMAB (ePoster Area [VIRTUAL]) -  Jan 30, 2022 - Abstract #EBMT2022EBMT_1219;    
     Cold agglutinin mediated hemolytic anemia post CAR-T cell treatment is a complex entity with lack of evidence based treatment . Anti CD38 monoclonal antibody daratumumab induces rapidly depletion of antibody producing plasma cells and can be an option in steroid, IVIG and Rituximab refractory cold agglutinin mediated autoimmune hemolytic anemia in CAR-T cell patients.
  • ||||||||||  ISIKOK-19 / Acıbadem Healthcare, Acıbadem University
    Trial primary completion date, CAR T-Cell Therapy:  ISIKOK-19: Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL (clinicaltrials.gov) -  Jan 27, 2020   
    P1/2,  N=24, Recruiting, 
    This is the first report of preclinical assessment of efficacy and safety analysis of CAR-T cells (ISIKOK-19) targeting CD19-expressing B cells in relapsed/refractory ALL and NHL patients in Turkey. Trial primary completion date: Jan 2020 --> Jan 2021